Advanced search
Publication Cover
Postgraduate Medicine Volume 126, 2014 - Issue 6
Submit an article Journal homepage
447
Views
55
CrossRef citations to date
0
Altmetric
Clinical Focus: Metabolic Syndrome, Diabetes, and Immunizations

Safety and Efficacy of Lorcaserin: A Combined Analysis of the BLOOM and BLOSSOM Trials

Louis Aronne Department of Medicine, Weill Cornell Medical College, New York City, NYCorrespondence[email protected]
, MD,
William Shanahan Clinical Development, Arena Pharmaceuticals Inc., San Diego, CA
, MD,
Randi Fain Eisai Medical and Scientific Affairs, Eisai Inc., Woodcliff Lake, NJ
, MD,
Alan Glicklich Clinical Development, Arena Pharmaceuticals Inc., San Diego, CA
, MD,
William Soliman Eisai Medical and Scientific Affairs, Eisai Inc., Woodcliff Lake, NJ
, PhD,
Yuhan Li Eisai Medical and Scientific Affairs, Eisai Inc., Woodcliff Lake, NJ
, MS &
Steven Smith Diabetes and Obesity Research Center, Sanford/Burnham Medical Research Institute at Lake Nona, Orlando, FL; Translational Research Institute for Metabolism and Diabetes, Florida Hospital, Orlando, FL
, MD show all
Pages 7-18 | Published online: 13 Mar 2015

Citations (55)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Fang Chen, Wenqing Su, Abhilasha Ramasamy, Tracy Zvenyach, Scott Kahan, Theodore Kyle & Rahul Ganguly. (2019) Ten-year Medicare budget impact of increased coverage for anti-obesity intervention. Journal of Medical Economics 22:10, pages 1096-1104.
Read now
Hubertus Himmerich & Janet Treasure. (2018) Psychopharmacological advances in eating disorders. Expert Review of Clinical Pharmacology 11:1, pages 95-108.
Read now
Richard Nesto, Randi Fain, Yuhan Li & William Shanahan. (2016) Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. Postgraduate Medicine 128:4, pages 364-370.
Read now
Alpana P Shukla, Rekha B Kumar & Louis J Aronne. (2015) Lorcaserin Hcl for the treatment of obesity. Expert Opinion on Pharmacotherapy 16:16, pages 2531-2538.
Read now

Articles from other publishers (51)

Mervin Chávez-Castillo, Pablo Duran, Bermary Garrido, Andrea Díaz, Daniel Escalona & Clímaco Cano. (2023) Obesity as a Neurobiologic Disorder: A Heavyweight Contender. Current Psychiatry Research and Reviews 19:2, pages 109-136.
Crossref
Paul J. Fletcher, Arya Rahbarnia, Zhaoxia Li, Xiaodong Ji, Guy A. Higgins, Douglas Funk & A.D. Lê. (2023) Effects of 5-HT2C receptor stimulation in male mice on behaviour and Fos expression: Feeding, reward and impulsivity. Behavioural Brain Research 447, pages 114438.
Crossref
Edmund Przegaliński, Kacper Witek, Karolina Wydra, Jolanta H. Kotlińska & Małgorzata Filip. (2023) 5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators. Nutrients 15:6, pages 1449.
Crossref
Eleni A. Karavia, Panagiota C. Giannopoulou, Vassiliki Konstantinopoulou, Katerina Athanasopoulou, Theodosios D. Filippatos, Demosthenes Panagiotakos & Kyriakos E. Kypreos. (2023) Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool. Nutrients 15:3, pages 606.
Crossref
Francisco Bandeira & Ana Maíra Quental da Nóbrega. 2022. Endocrinology and Diabetes. Endocrinology and Diabetes 435 442 .
Muhan Jing, Shanshan Wang, Ding Li, Zeyu Wang, Ziwen Li, Yichen Lu, Tong Sun, Chen Qiu, Fang Chen, Haijuan Yu & Wei Zhang. (2021) Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets. Frontiers in Pharmacology 12.
Crossref
Karine Suissa, Sebastian Schneeweiss, Dong Wook Kim & Elisabetta Patorno. (2021) Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States . Diabetes, Obesity and Metabolism 23:7, pages 1542-1551.
Crossref
Marcus May & Jens Jordan. (2021) Medikamentöse Therapie der Adipositas. Ärztliche Psychotherapie 16:1, pages 16-21.
Crossref
Kristen Piche, Uday Mann & Premal Patel. (2020) Treatment of Delayed Ejaculation. Current Sexual Health Reports 12:4, pages 251-260.
Crossref
Luiz Ricardo de Almeida Kiguti, Tainá Louise Pacheco, Edson Antunes & Wilma de Grava Kempinas. (2020) Lorcaserin Administration has Pro-Ejaculatory Effects in Rats via 5-HT2C Receptors Activation: A Putative Pharmacologic Strategy to Delayed Ejaculation?. The Journal of Sexual Medicine 17:6, pages 1060-1071.
Crossref
Sanjay Sharma, Komal S. Aware, Ketan Hatware & Kiran Patil. (2020) Chemistry, Analysis, Pharmacokinetics and Pharmacodynamics Aspects of Lorcaserin, a Selective Serotonin 5-HT2C Receptor Agonist: An Update. Mini-Reviews in Medicinal Chemistry 20:9, pages 768-778.
Crossref
Carolyn T. Bramante, Sarah Raatz, Eric M. Bomberg, Megan M. Oberle & Justin R. Ryder. (2020) Cardiovascular Risks and Benefits of Medications Used for Weight Loss. Frontiers in Endocrinology 10.
Crossref
Marcus May, Christoph Schindler & Stefan Engeli. (2020) Modern pharmacological treatment of obese patients. Therapeutic Advances in Endocrinology and Metabolism 11, pages 204201881989752.
Crossref
Guy A. Higgins, Paul J. Fletcher & William R. Shanahan. (2020) Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential. Pharmacology & Therapeutics 205, pages 107417.
Crossref
Leonardo B. Silenieks, Nicole K. Carroll, Annalise Van Niekerk, Emily Van Niekerk, Colleen Taylor, Neil Upton & Guy A. Higgins. (2019) Evaluation of Selective 5-HT 2C Agonists in Acute Seizure Models . ACS Chemical Neuroscience 10:7, pages 3284-3295.
Crossref
K. Fujioka, M. Malhotra, C. Perdomo & C. M. Apovian. (2019) Effect of lorcaserin in different age groups: a post hoc analysis of patients from the BLOOM, BLOSSOM and BLOOM‐DM studies. Obesity Science & Practice 5:2, pages 120-129.
Crossref
Fernando B. de Moura, Stephen J. Kohut & Jack Bergman. 2019. Neuropsychotherapeutics. Neuropsychotherapeutics 197 236 .
H. Bays, C. Perdomo, E. Nikonova, R. Knoth & M. Malhotra. (2018) Lorcaserin and metabolic disease: weight‐loss dependent and independent effects. Obesity Science & Practice 4:6, pages 499-505.
Crossref
Giuseppe D'Agostino, David Lyons, Claudia Cristiano, Miriam Lettieri, Cristian Olarte-Sanchez, Luke K. Burke, Megan Greenwald-Yarnell, Celine Cansell, Barbora Doslikova, Teodora Georgescu, Pablo Blanco Martinez de Morentin, Martin G. MyersJr.Jr., Justin J. Rochford & Lora K. Heisler. (2018) Nucleus of the Solitary Tract Serotonin 5-HT2C Receptors Modulate Food Intake. Cell Metabolism 28:4, pages 619-630.e5.
Crossref
Daniel E. Felsing, Noelle C. Anastasio, Joanna M. Miszkiel, Scott R. Gilbertson, John A. Allen & Kathryn A. Cunningham. (2018) Biophysical validation of serotonin 5-HT2A and 5-HT2C receptor interaction. PLOS ONE 13:8, pages e0203137.
Crossref
Amanda E. Price, Noelle C. Anastasio, Sonja J. Stutz, Jonathan D. Hommel & Kathryn A. Cunningham. (2018) Serotonin 5-HT2C Receptor Activation Suppresses Binge Intake and the Reinforcing and Motivational Properties of High-Fat Food. Frontiers in Pharmacology 9.
Crossref
Gitanjali Srivastava & Caroline Apovian. (2018) Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon. Current Obesity Reports 7:2, pages 147-161.
Crossref
Donald E. Greydanus, Marisha Agana, Manmohan K. Kamboj, Saad Shebrain, Neelkamal Soares, Ransome Eke & Dilip R. Patel. (2018) Pediatric obesity: Current concepts. Disease-a-Month 64:4, pages 98-156.
Crossref
Marcio C. Mancini & Maria Edna de Melo. (2017) The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. Diabetology & Metabolic Syndrome 9:1.
Crossref
Andrew J. Krentz & Gerardo Rodriguez-Araujo. (2017) Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development. Pharmaceutical Medicine 31:6, pages 399-421.
Crossref
Peter G Clifton. (2017) Neural circuits of eating behaviour: Opportunities for therapeutic development. Journal of Psychopharmacology 31:11, pages 1388-1402.
Crossref
Guy A Higgins, Fiona D Zeeb & Paul J Fletcher. (2017) Role of impulsivity and reward in the anti-obesity actions of 5-HT 2C receptor agonists . Journal of Psychopharmacology 31:11, pages 1403-1418.
Crossref
Guy A. Higgins. (2017) 18 F-FPP: A PET Ligand for the 5-HT 2C Receptor? . ACS Chemical Neuroscience 8:5, pages 904-907.
Crossref
Guy A. Higgins, Leonardo B. Silenieks, Amy Patrick, Ines A. M. De Lannoy, Paul J. Fletcher, Linda A. Parker, Neil J. MacLusky, Laura C. Sullivan, Teresa A. Chavera & Kelly A. Berg. (2017) Studies To Examine Potential Tolerability Differences between the 5-HT 2C Receptor Selective Agonists Lorcaserin and CP-809101 . ACS Chemical Neuroscience 8:5, pages 1074-1084.
Crossref
Steven R. Smith, W. Timothy Garvey, Frank L. Greenway, Sharon Zhou, Randi Fain, Robert Pilson, Ken Fujioka & Louis J. Aronne. (2017) Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. Obesity 25:5, pages 857-865.
Crossref
Faidon Magkos, Elena Nikonova, Randi Fain, Sharon Zhou, Tony Ma & William Shanahan. (2017) Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus. Obesity 25:5, pages 842-849.
Crossref
Kenya D. Palmer & Caroline M. Apovian. 2017. Nutrition in the Prevention and Treatment of Disease. Nutrition in the Prevention and Treatment of Disease 477 498 .
Neil J. Weissman, Steven R. Smith, Randi Fain, Nancy Hall & William R. Shanahan. (2017) Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials. Obesity 25:1, pages 39-44.
Crossref
Patrick M. O'Neil, W. Timothy Garvey, J. Michael Gonzalez-Campoy, Pablo Mora, Rafael Violante Ortiz, German Guerrero, Birgitte Claudius & Xavier Pi-Sunyer. (2016) Effects of Liraglutide 3.0 Mg on Weight and Risk Factors in Hispanic Versus Non-Hipanic Populations: Subgroup Analysis from Scale Randomized Trials. Endocrine Practice 22:11, pages 1277-1287.
Crossref
Candida J. Rebello & Frank L. Greenway. (2016) Reward-Induced Eating: Therapeutic Approaches to Addressing Food Cravings. Advances in Therapy 33:11, pages 1853-1866.
Crossref
F. L. Greenway, W. Shanahan, R. Fain, T. Ma & D. Rubino. (2016) Safety and tolerability review of lorcaserin in clinical trials. Clinical Obesity 6:5, pages 285-295.
Crossref
Ronald Christopher, Mike Morgan, Jim Ferry, Bhaskar Rege, Yong Tang, Allan Kristensen & William Shanahan. (2016) Single- and Multiple-dose Pharmacokinetics of a Lorcaserin Extended-release Tablet. Clinical Therapeutics 38:10, pages 2227-2238.e4.
Crossref
Kate Millar & Ruth Poole. (2016) Current drugs for weight loss. Practical Diabetes 33:7, pages 229-232.
Crossref
Catherine E. Thomas, Elizabeth A. Mauer, Alpana P. Shukla, Samrat Rathi & Louis J. Aronne. (2016) Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity 24:9, pages 1955-1961.
Crossref
Guy A. Higgins, Leo B. Silenieks, Everett B. Altherr, Cam MacMillan, Paul J. Fletcher & Wayne E. Pratt. (2016) Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists. Psychopharmacology 233:14, pages 2841-2856.
Crossref
J. Ard, A. Cannon, C. E. Lewis, H. Lofton, T. Vang Skjøth, B. Stevenin & X. Pi-Sunyer. (2016) Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. Diabetes, Obesity and Metabolism 18:4, pages 430-435.
Crossref
Knut Mai. (2016) Ansätze wider den großen Appetit. Info Diabetologie 10:2, pages 47-53.
Crossref
Amal A. Bajrai, Essam Ezzeldin, Khalid A. Al-Rashood, Mohammad Raish & Muzaffar Iqbal. (2016) A Validated UPLC–MS-MS Assay for the Rapid Determination of Lorcaserin in Plasma and Brain Tissue Samples. Journal of Analytical Toxicology 40:2, pages 133-139.
Crossref
Jessica A. Darnobid & Stephanie B. Jones. (2016) The Perioperative Implications of New Weight Loss Drugs. Advances in Anesthesia 34:1, pages 1-11.
Crossref
Wayne Rankin & Gary Wittert. (2015) Anti-obesity drugs. Current Opinion in Lipidology 26:6, pages 536-543.
Crossref
Jonathan R. S. Arch. (2015) Horizons in the Pharmacotherapy of Obesity. Current Obesity Reports 4:4, pages 451-459.
Crossref
Lehel Simon. (2015) Our Psycho-Neurodiabetological Concept. Journal of Diabetes, Metabolic Disorders & Control 2:3.
Crossref
Guy A. Higgins & Paul J. Fletcher. (2015) Therapeutic Potential of 5-HT 2C Receptor Agonists for Addictive Disorders . ACS Chemical Neuroscience 6:7, pages 1071-1088.
Crossref
L. K. Burke & L. K. Heisler. (2015) 5-Hydroxytryptamine Medications for the Treatment of Obesity. Journal of Neuroendocrinology 27:6, pages 389-398.
Crossref
Richard J. Ward, John D. Pediani, Antoine G. Godin & Graeme Milligan. (2015) Regulation of Oligomeric Organization of the Serotonin 5-Hydroxytryptamine 2C (5-HT2C) Receptor Observed by Spatial Intensity Distribution Analysis. Journal of Biological Chemistry 290:20, pages 12844-12857.
Crossref
Nicholas T. Bello. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions 1 13 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.